Abstracts tagged "radiography and rheumatoid arthritis (RA)"

Abstract Number: 1012 • 2012 ACR/ARHP Annual Meeting
Radiographic Deformity of the Foot Is Starting From the Early Stage of Rheumatoid Arthritis
Kenji Mamoto¹, Tatsuya Koike², Tadashi Okano¹, Atsuko Kamiyama², Yuko Sugioka¹, Masahiro Tada¹ and Hiroaki Nakamura¹, ¹Orthopedic Surgery, Osaka City University Graduate School of Medicine, Osaka, Japan, ²Rheumatosurgery, Osaka City University Graduate School of Medicine, Osaka, Japan
Background/Purpose: Foot deformities frequently arise in patients with rheumatoid arthritis (RA). It might cause gait dysfunction and lead to disability. However, the precise mechanism of…
Abstract Number: 981 • 2012 ACR/ARHP Annual Meeting
Aggregated Genetic Information Explains Variations On Hand Radiographic Scores in Rheumatoid Arthritis Patient
Jing Cui¹, Nancy A. Shadick², Katherine P. Liao³, Michael Weinblatt⁴, Robert M. Plenge⁵ and Elizabeth W. Karlson³, ¹Rheumatology, Brigham and Women's Hospital, Boston, MA, ²Rheumatology/Immunology, Brigham and Women's Hospital, Boston, MA, ³Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁴Rheumatology & Immunology, Brigham & Women's Hospital, Boston, MA, ⁵Division of Rheumatology, Immunology and Allergy and Division of Genetics, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Rheumatoid arthritis (RA) has an estimated heritability of approximately 60%. Joint destruction as a severity measure of RA is influenced by genetic factors, however…
Abstract Number: 812 • 2012 ACR/ARHP Annual Meeting
Intravenous Golimumab Inhibits Radiographic Progression and Maintains Clinical Efficacy and Safety in Patients with Active Rheumatoid Arthritis Despite Methotrexate Therapy: 1-Year Results of a Phase 3 Trial
Michael Weinblatt¹, Clifton O. Bingham III², Alan Mendelsohn³, Lenore Noonan⁴, Shihong Sheng⁵, Lilianne Kim⁶, Kim Hung⁶, Jiandong Lu⁶, Daniel Baker⁶ and Rene Westhovens⁷, ¹Rheumatology & Immunology, Brigham & Women's Hospital, Boston, MA, ²Department of Medicine, Johns Hopkins University, Baltimore, MD, ³Immunology, Janssen Research & Development, LLC, Spring House, PA, ⁴Immunology, Janssen Research & Development, LLC., Spring House, PA, ⁵Biostatistics, Janssen Research & Development, LLC, Spring House, PA, ⁶Janssen Research & Development, LLC, Spring House, PA, ⁷Rheumatology, University Hospital KU Leuven, Leuven, Belgium
Intravenous Golimumab Inhibits Radiographic Progression and Maintains Clinical Efficacy and Safety in Patients with Active Rheumatoid Arthritis Despite Methotrexate Therapy: 1-Year Results of a Phase…
Abstract Number: 766 • 2012 ACR/ARHP Annual Meeting
Anemia May Provide Clinically Relevant Information Beyond Conventional Disease Activity Assessment to Predict Radiographic Damage Progression in Rheumatoid Arthritis
Burkhard Moller¹, Frauke Förger², Peter M. Villiger³ and Axel Finckh⁴, ¹Rheumatology, Inselspital University Hospital, Bern, Switzerland, ²Rheumatology, Clinical Immunology and Allergology, Inselspital University Hospital of Bern, Bern, Switzerland, ³Rheumatology, Immunology and Allergology, University Hospital Bern, Bern, Switzerland, ⁴Rheumatology, Geneva University Hospitals, Geneva 14, Switzerland
Anemia may provide clinically relevant information beyond conventional disease activity assessment to predict radiographic damage progression in Rheumatoid ArthritisBurkhard Möller, Frauke Förger, Peter M. Villiger,…
Abstract Number: 2142 • 2012 ACR/ARHP Annual Meeting
Magnetic Resonance Imaging-Proven Osteitis At Baseline Predicts the Early Rheumatoid Arthritis Patients Who Will Develop Rapid Radiographic Progression: MRI Is Beneficial to Find the Window of Opportunity in Early RA
Mami Tamai¹, Yoshikazu Nakashima², Takahisa Suzuki³, Yoshiro Horai², Akitomo Okada⁴, Junko Kita⁴, Shin-ya Kawashiri², Naoki Iwamoto⁴, Kunihiro Ichinose⁵, Kazuhiko Arima⁴, Hideki Nakamura¹, Tomoki Origuchi⁶, Masataka Uetani⁷, Kiyoshi Aoyagi⁸, Katsumi Eguchi⁹ and Atsushi Kawakami², ¹Department of Immunology and Rheumatology, Nagasaki University, Nagasaki, Japan, ²Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ³Unit of Translational Medicine, Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ⁴Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ⁵Department of Immunology and Rheumatology, Unit of Translational Medicine, Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ⁶Department of Health Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ⁷Department of Radiology and Radiation Research, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ⁸Department of Public Health, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ⁹Sasebo City General Hospital, Sasebo, Nagasaki, Japan
Background/Purpose: Window of opportunity exists in the earlier phase of rheumatoid arthritis (RA), thus, early recognition of the RA patients who will develop rapid radiographic…
Abstract Number: 770 • 2012 ACR/ARHP Annual Meeting
Is Late Onset Rheumatoid Arthritis (LORA) Really a Distinct Entity of RA? Results From the Swiss Observational Cohort
Ruediger Mueller¹, Toni Kaegi¹, Axel Finckh² and Johannes von Kempis¹, ¹Rheumatology, Kantonsspital St. Gallen, St. Gallen, Switzerland, ²Rheumatology, Geneva University Hospitals, Geneva 14, Switzerland
Background/Purpose: Rheumatoid arthritis (RA) is generally described as a disease with two peaks of onset, either late (late onset RA, LORA) or early (young onset…
Abstract Number: 2133 • 2012 ACR/ARHP Annual Meeting
Relationship Between Clinical Response and Radiographic Outcomes in Patients with Moderate Rheumatoid Arthritis
Josef S. Smolen¹, Ronald F. van Vollenhoven², Andrew S. Koenig³, Ronald Pedersen³, Annette Szumski⁴ and Eustratios Bananis⁴, ¹Department of Rheumatology, Medical University of Vienna and Hietzing Hospital, Vienna, Austria, ²Unit for Clinical Trial Therapy research, The Karolinska Institute, Stockholm, Sweden, ³Specialty Care, Pfizer Inc, Collegeville, PA, ⁴Specialty Care, Pfizer Inc., Collegeville, PA
Background/Purpose: Clinical evidence has established the importance of early, intensive treatment of rheumatoid arthritis (RA) to decrease disease activity and prevent joint damage.1 The objective…
Abstract Number: 403 • 2012 ACR/ARHP Annual Meeting
The Impact of Reaching Low Disease Activity in the First Year On Future Disability and Damage in Patients with Early Rheumatoid Arthritis
Pooneh Akhavan¹, George A. Tomlinson², Paul R. Fortin³ and Claire Bombardier¹, ¹Rheumatology, University of Toronto, Toronto, ON, Canada, ²Dept of Medicine/Rheumatology, Toronto General Hospital, Toronto, ON, Canada, ³Medicine, Centre de Recherche du Chu de Québec et Université Laval, Quebec City, QC, Canada
Background/Purpose: Remission has been proposed as the goal of treatment in patients with early rheumatoid arthritis (RA) by current clinical practice guidelines. Remission is ideal…
Abstract Number: 2136 • 2012 ACR/ARHP Annual Meeting
Alcohol Use and Radiographic Disease Progression in African Americans with Recent Onset Rheumatoid Arthritis
Marshall Davis¹, Kaleb Michaud¹, Harlan Sayles¹, Doyt L. Conn², Larry W. Moreland³, S. Louis Bridges Jr.⁴ and Ted R. Mikuls¹, ¹Internal Medicine, University of Nebraska Medical Center, Omaha, NE, ²Rheumatology, Emory Univ School of Medicine, Atlanta, GA, ³Division of Rheumatology & Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ⁴Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Previous studies have shown that alcoholic beverage consumption can modify levels of circulating inflammatory cytokines and alter expression of innate immune system receptors. Recognizing…
Abstract Number: 370 • 2012 ACR/ARHP Annual Meeting
Characteristic of the Japanese Patients with Rheumatoid Arthritis (RA) of Rapid Radiographic Progression (RRP) Treated with Synthetic Disease Modifying Anti-Rheumatic Drugs (DMARDs) in Daily Practice: A Large-Scale Prospective Longitudinal Cohort Study (the 1st report of Apple Survey)
Akitomo Okada¹, Atsushi Kawakami², Takaaki Fukuda³, Toshihiko Hidaka⁴, Tomonori Ishii⁵, Yukitaka Ueki⁶, Takao Kodera⁷, Munetoshi Nakashima⁸, Yuichi Takahashi⁹, Seiyo Honda¹⁰, Yoshiro Horai², Tomohiro Koga¹, Ryu Watanabe¹¹, Hiroshi Okuno¹² and Katsumi Eguchi¹³, ¹Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ²Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ³Center for Rheumatic Diseases, Kurume University Medical Center, Kurume, Japan, ⁴Zenjinkai Shimin-No-Mori Hospital, Miyazaki, Japan, ⁵Department of Hematology and Rheumatology, Tohoku University, Sendai, Japan, ⁶Sasebo Chuo Hospital, Sasebo, Japan, ⁷Tohoku Kosei Nenkin Hospital, Sendai, Japan, ⁸Japanese Red Cross Nagasaki Genbaku Hospital, Nagasaki, Japan, ⁹Yu Family Clinic, Sendai, Japan, ¹⁰Kurume University School of Medicene, Kurume, Japan, ¹¹Department of Hematology and Rheumatology, Tohoku University Hospital, Sendai, Japan, ¹²Tohoku University Hospital, Sendai, Japan, ¹³Sasebo City General Hospital, Sasebo, Nagasaki, Japan
Background/Purpose: There has been few epidemiological report of longitudinal radiographic progression in rheumatoid arthritis (RA) patients captured in daily practice. In 20 related-centers of the…
Abstract Number: 2114 • 2012 ACR/ARHP Annual Meeting
Joint Damage Progression in Rheumatoid Arthritis: Role of the HLA-DRB1 Shared Epitope and Anti-CCP
Jose Felix Restrepo¹, Inmaculada del Rincon¹, Roy W. Haas², Daniel F. Battafarano³ and Agustin Escalante², ¹Rheumatology, University of Texas Health Science Center at San Antonio, San Antonio, TX, ²Dept. of Medicine-Rheumatology, University of Texas Health Science Center at San Antonio, San Antonio, TX, ³Medicine / MCHE-MDR, Brooke Army Medical Ctr, San Antonio, TX
Background/Purpose: The HLA-DRB1 shared epitope (SE) and antibodies to cyclic citrullinated peptides (anti-CCP) are important to the susceptibility to rheumatoid arthritis (RA), and are thought…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].